Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310417 | 1.00 | B3GNT2 (0.36) | B3GNT2IDH1S1PR4S1PR3MEN1 | |
| SCHEMBL12310007 | 1.00 | B3GNT2 (0.36) | B3GNT2IDH1S1PR4S1PR3MEN1 | |
| SCHEMBL15345244 | 1.00 | B3GNT2 (0.36) | B3GNT2IDH1S1PR4S1PR3MEN1 | |
| SCHEMBL30458227 | 1.00 | B3GNT2 (0.36) | B3GNT2IDH1S1PR4S1PR3MEN1 | |
| SCHEMBL2394129 | 1.00 | B3GNT2 (0.36) | B3GNT2IDH1S1PR4S1PR3MEN1 | |
| SCHEMBL22159231 | 1.00 | B3GNT2 (0.36) | B3GNT2IDH1S1PR4S1PR3MEN1 | |
| SCHEMBL3238364 | 0.82 | HDAC6 (0.41) | — | |
| SCHEMBL20758639 | 0.82 | B3GNT2 (0.36) | B3GNT2S1PR4S1PR3 | |
| SCHEMBL20758632 | 0.82 | B3GNT2 (0.36) | B3GNT2S1PR4S1PR3 | |
| SCHEMBL346024 | 0.82 | HDAC6 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825666-B | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-114127060-B | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20220267309-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-08-25 | — | — | US | disclosed |
| US-20220267309-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-08-25 | — | — | US | disclosed |
| EP-3964508-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| EP-3964508-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-114127060-A | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020216071-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216071-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-111825666-A | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | B3GNT2 3171/4885IDH1 1/4885S1PR4 4881/4885 |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | B3GNT2 3243/4885IDH1 22/4885S1PR4 4253/4885 |
| US-20220267309-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | IDH3B, IDH1, IDH3A | B3GNT2 3844/4885IDH1 2/4885S1PR4 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.